Web Desc
Cancer Evolution and Combinatorial Cancer Therapies: Concepts and Challenges
Organizer(s): William Sellers, Charles Swanton and Lillian Siu
Date: January 19 - 23, 2020
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by BioLegend, Inc., Incyte Corporation, Merck & Co., Inc., Novartis Institutes for BioMedical Research and Roche
Summary of Meeting:
Progress in understanding the clonal and sub-clonal processes driving tumor evolution, tumor heterogeneity, the mechanisms of therapeutic resistance, and in defining new cancer dependencies have converged to help inform more rational approaches to achieving the development of transformative combination therapeutic regimens in cancer. Nonetheless, examples of highly effective rationally elucidated combinations remain rare and the pre-clinical and clinical development challenges to this goal are substantial. As an example, the emergent role of immunotherapeutics having curative potential has led to tremendous excitement, yet increased complexity. The broad swath of empiric based clinical trials attests to the continued and growing need for improved pre-clinical means by which transformative combinations can be identified. This conference will bring together evolutionary and computational biologists, experts in functional genomics, translational scientists, drug discovery researchers and physician leaders in clinical development. The conference program begins with how evolutionary processes drive the “natural” progression of cancer and how such processes lead to the measured heterogeneous populations of cells resident in all tumors. These two related forces, driven at least in part by ongoing mutational processes, then combine to give rise to therapeutic resistance, which enables researchers to robustly identify mechanisms relevant to humans in pre-clinical models. The deeper understanding of these forces can inform specific combination therapeutics, but combination hypotheses are now being discovered though genome-scale functional screening approaches (e.g. CRISPR, shRNA). Speakers have been invited to discuss the studies which are now taking place in both the targeted and immuno-oncology (I/O) therapeutic fields. These talks filter into sessions on understanding how I/O and targeted therapeutics are similar or distinct and to seek the lessons from the clinical trial outputs in the I/O field that will emerge over the next year. Finally, clinical development paradigms for more rapidly testing and developing combinations will be covered during the conference.
Scholarship Deadline: September 25 2019
Discounted Abstract Deadline: September 25 2019
Abstract Deadline: October 17 2019
Discounted Registration Deadline: November 20 2019
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
BioLegend, Inc.Incyte CorporationMerck & Co., Inc.Novartis Institutes for BioMedical ResearchRoche
We gratefully acknowledge additional support from these exhibitors at this conference:
American Association for Cancer Research (AACR)Myriad-RBM
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Incyte Corporation
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA246935-01
Funding for this conference was made possible (in part) by 1R13CA246935-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, January 19 | 4:00PM - 8:00PM
Arrival and Registration
Room: Riverview Lounge


Sunday, January 19 | 6:00PM - 8:00PM
Welcome Mixer
Room: Riverview Lounge
No registration fees are used to fund alcohol served at this function.

Monday, January 20 | 7:00AM - 8:00AM
Breakfast
Room: Alberta/New Brunswick


Monday, January 20 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Cascade Ballroom

Speaker 1 of 2
* William R. Sellers, Broad Institute of MIT and Harvard, USA

Monday, January 20 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Cascade Ballroom

Speaker 2 of 2
Charles Swanton, Francis Crick Institute, UK
Cancer Evolution and Immune Escape: TRACERx

Monday, January 20 | 9:00AM - 11:30AM
The Evolution of Cancer I
Room: Cascade Ballroom

Speaker 1 of 6
* Jens Lagergren, KTH Royal Institute of Technology, Sweden

Monday, January 20 | 9:00AM - 11:30AM
The Evolution of Cancer I
Room: Cascade Ballroom

Speaker 2 of 6
Carlo Maley, Arizona State University, USA
Lessons in Cancer Prevention from Whales and Other Animals

Monday, January 20 | 9:00AM - 11:30AM
The Evolution of Cancer I
Room: Cascade Ballroom


Coffee Break

Monday, January 20 | 9:00AM - 11:30AM
The Evolution of Cancer I
Room: Cascade Ballroom

Speaker 4 of 6
Trevor A. Graham, Queen Mary University of London, UK
Evolution of Copy Number Alterations in Colon Cancer

Monday, January 20 | 9:00AM - 11:30AM
The Evolution of Cancer I
Room: Cascade Ballroom

Speaker 5 of 6
Natalie Andersson, Lund University, Sweden
Short Talk: High-Risk Pediatric Cancer Genomes are Shaped by Intense Phylogenetic Branching Emerging at Specific Points in Evolutionary History


Monday, January 20 | 9:00AM - 11:30AM
The Evolution of Cancer I
Room: Cascade Ballroom

Speaker 6 of 6
Floris P. Barthel, The Jackson Laboratory, USA
Short Talk: Longitudinal Molecular Trajectories of Diffuse Glioma in Adults

Monday, January 20 | 11:30AM - 5:00PM
On Own for Lunch


Monday, January 20 | 11:30AM - 1:00PM
Poster Setup
Room: Alberta/New Brunswick


Monday, January 20 | 1:00PM - 10:00PM
Poster Viewing
Room: Alberta/New Brunswick


Monday, January 20 | 2:30PM - 4:30PM
Career Roundtable
Room: New Brunswick
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Speaker 1 of 4
Sohrab Shah, Memorial Sloan Kettering Cancer Center, USA

Monday, January 20 | 2:30PM - 4:30PM
Career Roundtable
Room: New Brunswick
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Speaker 2 of 4
Jeffrey A. Engelman, Novartis Institutes for BioMedical Research, USA

Monday, January 20 | 2:30PM - 4:30PM
Career Roundtable
Room: New Brunswick
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Speaker 3 of 4
Amanda Magara, American Association for Cancer Research, USA

Monday, January 20 | 2:30PM - 4:30PM
Career Roundtable
Room: New Brunswick
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Speaker 4 of 4
Tatiana Prowell, U.S. FDA and Johns Hopkins University, USA

Monday, January 20 | 4:30PM - 5:00PM
Coffee Available
Room: Riverview Lounge


Monday, January 20 | 5:00PM - 7:00PM
The Evolution of Cancer II
Room: Cascade Ballroom

Speaker 1 of 6
* Lisa Tucker-Kellogg, Duke-NUS Medical School Singapore, Singapore

Monday, January 20 | 5:00PM - 7:00PM
The Evolution of Cancer II
Room: Cascade Ballroom

Speaker 2 of 6
Andrea Sottoriva, Institute of Cancer Research, UK
Harnessing Evolutionary Steering in Cancer Therapy to Control Drug Resistance

Monday, January 20 | 5:00PM - 7:00PM
The Evolution of Cancer II
Room: Cascade Ballroom

Speaker 3 of 6
Giovanni Ciriello, University of Lausanne, Switzerland
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies

Monday, January 20 | 5:00PM - 7:00PM
The Evolution of Cancer II
Room: Cascade Ballroom

Speaker 4 of 6
Christina Curtis, Stanford University, USA
Quantifying Clonal Evolution Through Treatment and Metastasis

Monday, January 20 | 5:00PM - 7:00PM
The Evolution of Cancer II
Room: Cascade Ballroom

Speaker 5 of 6
Sarah J. Aitken, University of Cambridge, UK
Short Talk: Pervasive Segregation of DNA Lesions Generates Genetic Diversity in Cancer

Monday, January 20 | 5:00PM - 7:00PM
The Evolution of Cancer II
Room: Cascade Ballroom

Speaker 6 of 6
James R. Torpy, Garvan Institute of Medical Research, Australia
Short Talk: Copy Number Variation Profiles Derived from Single Cell RNA-Sequencing Data Reveals Diverse Intra-Tumour Heterogeneity across Multiple Breast Cancer Subtypes

Monday, January 20 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Alberta/New Brunswick
No registration fees are used to fund alcohol served at this function.

Monday, January 20 | 7:30PM - 10:00PM
Poster Session 1
Room: Alberta/New Brunswick


Tuesday, January 21 | 7:00AM - 8:00AM
Breakfast
Room: Alberta/New Brunswick


Tuesday, January 21 | 8:00AM - 11:15AM
Cancer Heterogeneity
Room: Cascade Ballroom

Speaker 1 of 9
* Karin Jirström, Lund University, Sweden

Tuesday, January 21 | 8:00AM - 11:15AM
Cancer Heterogeneity
Room: Cascade Ballroom

Speaker 2 of 9
Sorana Morrissy, University of Calgary, Canada
Tracking Intra-Tumor Heterogeneity in Brain Tumors

Tuesday, January 21 | 8:00AM - 11:15AM
Cancer Heterogeneity
Room: Cascade Ballroom

Speaker 3 of 9
Jeffrey A. Engelman, Novartis Institutes for BioMedical Research, USA
The Therapeutic Implications for Cancer Heterogeneity

Tuesday, January 21 | 8:00AM - 11:15AM
Cancer Heterogeneity
Room: Cascade Ballroom


Coffee Break

Tuesday, January 21 | 8:00AM - 11:15AM
Cancer Heterogeneity
Room: Cascade Ballroom

Speaker 5 of 9
Sohrab Shah, Memorial Sloan Kettering Cancer Center, USA
Clonal Genotype and Population Structure Inference from Single-Cell Tumor Sequencing

Tuesday, January 21 | 8:00AM - 11:15AM
Cancer Heterogeneity
Room: Cascade Ballroom

Speaker 6 of 9
Thomas G. Graeber, University of California, Los Angeles, USA
Pan-Cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies

Tuesday, January 21 | 8:00AM - 11:15AM
Cancer Heterogeneity
Room: Cascade Ballroom

Speaker 7 of 9
Anneleen Daemen, ORIC Pharmaceuticals, USA
Short Talk: Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Therapeutic Vulnerabilities in Lung Cancer

Tuesday, January 21 | 8:00AM - 11:15AM
Cancer Heterogeneity
Room: Cascade Ballroom

Speaker 8 of 9
David Gisselsson Nord, Lund University, Sweden
Short Talk: Clonal Dynamics Under Therapy in Neuroblastoma

Tuesday, January 21 | 8:00AM - 11:15AM
Cancer Heterogeneity
Room: Cascade Ballroom

Speaker 9 of 9
Hunter Shain, University of California, San Francisco, USA
Short Talk: The Genetic Evolution of Metastatic Uveal Melanoma


Tuesday, January 21 | 11:15AM - 5:00PM
On Own for Lunch


Tuesday, January 21 | 11:15AM - 1:00PM
Poster Setup
Room: Alberta/New Brunswick


Tuesday, January 21 | 1:00PM - 10:00PM
Poster Viewing
Room: Alberta/New Brunswick


Tuesday, January 21 | 4:30PM - 5:00PM
Coffee Available
Room: Riverview Lounge


Tuesday, January 21 | 5:00PM - 7:00PM
Understanding Checkpoints and Resistance in Immuno-Oncology
Room: Cascade Ballroom

Speaker 1 of 5
* Anna Vilgelm, Ohio State University, USA

Tuesday, January 21 | 5:00PM - 7:00PM
Understanding Checkpoints and Resistance in Immuno-Oncology
Room: Cascade Ballroom

Speaker 2 of 5
Marios Giannakis, Dana-Farber Cancer Institute, USA
Identification of Modulators of Immune Response from the Clinic: Implications for Combining I/O Agents


Tuesday, January 21 | 5:00PM - 7:00PM
Understanding Checkpoints and Resistance in Immuno-Oncology
Room: Cascade Ballroom

Speaker 3 of 5
Elisabeth G.E. de Vries, Universitair Medisch Centrum Groningen, Netherlands
Molecular Imaging for Immunotherapy

Tuesday, January 21 | 5:00PM - 7:00PM
Understanding Checkpoints and Resistance in Immuno-Oncology
Room: Cascade Ballroom

Speaker 4 of 5
Ashley DiMarco, Duke University, USA
Short Talk: APOBEC Mutagenesis as a Driver of Tumor Evolution through Tumor Cell-Intrinsic Mechanisms and by Modulating Tumor-Immune System Interactions


Tuesday, January 21 | 5:00PM - 7:00PM
Understanding Checkpoints and Resistance in Immuno-Oncology
Room: Cascade Ballroom

Speaker 5 of 5
Fernando Souza-Fonseca-Guimaraes, University of Queensland, Australia
Short Talk: Therapeutic Blockade of TGF-ß Superfamily Members Improves NK Cell Function and Anti-Tumor Immunity

Tuesday, January 21 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Alberta/New Brunswick
No registration fees are used to fund alcohol served at this function.

Tuesday, January 21 | 7:30PM - 10:00PM
Poster Session 2
Room: Alberta/New Brunswick


Wednesday, January 22 | 7:00AM - 8:00AM
Breakfast
Room: Alberta/New Brunswick


Wednesday, January 22 | 8:00AM - 11:00AM
Leveraging Therapeutic Resistance towards Combination Therap
ies

Room: Cascade Ballroom

Speaker 1 of 8
* Darrin D. Stuart, Novartis, USA

Wednesday, January 22 | 8:00AM - 11:00AM
Leveraging Therapeutic Resistance towards Combination Therap
ies

Room: Cascade Ballroom

Speaker 2 of 8
Poulikos I. Poulikakos, Icahn School of Medicine at Mount Sinai, USA
Adaptive Resistance Mechanisms and Next Generation Therapeutic Strategies for MAPK-Driven Cancers

Wednesday, January 22 | 8:00AM - 11:00AM
Leveraging Therapeutic Resistance towards Combination Therap
ies

Room: Cascade Ballroom

Speaker 3 of 8
Gaddy Getz, Broad Institute, USA
The Elucidation of Drivers of Therapeutic Resistant from Large-Scale Patient Sample Analysis

Wednesday, January 22 | 8:00AM - 11:00AM
Leveraging Therapeutic Resistance towards Combination Therap
ies

Room: Cascade Ballroom


Coffee Break

Wednesday, January 22 | 8:00AM - 11:00AM
Leveraging Therapeutic Resistance towards Combination Therap
ies

Room: Cascade Ballroom

Speaker 5 of 8
Aaron N. Hata, Massachusetts General Hospital, USA
Evolution of Acquired Resistance to Targeted Therapies for Lung Cancer

Wednesday, January 22 | 8:00AM - 11:00AM
Leveraging Therapeutic Resistance towards Combination Therap
ies

Room: Cascade Ballroom

Speaker 6 of 8
Himisha Beltran, Dana Farber Cancer Institute, USA
Lineage Plasticity and the Neuroendocrine Phenotype as a Resistance Mechanism in Prostate Cancer

Wednesday, January 22 | 8:00AM - 11:00AM
Leveraging Therapeutic Resistance towards Combination Therap
ies

Room: Cascade Ballroom

Speaker 7 of 8
Matthew J. Martin, AstraZeneca, UK
Short Talk: Eliminating Osimertinib Drug Tolerant Persister Cells Via Activation of the Extrinsic Apoptosis Pathway


Wednesday, January 22 | 8:00AM - 11:00AM
Leveraging Therapeutic Resistance towards Combination Therap
ies

Room: Cascade Ballroom

Speaker 8 of 8
Sean Misek, Michigan State University, USA
Short Talk: Identification of Pharmacological Vulnerabilities in BRAFi-Resistant Melanoma

Wednesday, January 22 | 11:00AM - 5:00PM
On Own for Lunch


Wednesday, January 22 | 11:00AM - 1:00PM
Poster Setup
Room: Alberta/New Brunswick


Wednesday, January 22 | 1:00PM - 10:00PM
Poster Viewing
Room: Alberta/New Brunswick


Wednesday, January 22 | 4:30PM - 5:00PM
Coffee Available
Room: Riverview Lounge


Wednesday, January 22 | 5:00PM - 7:00PM
The Preclinical Modeling and Discovery of Combinations
Room: Cascade Ballroom

Speaker 1 of 6
* Dieter Saur, Technical University Munich, Germany

Wednesday, January 22 | 5:00PM - 7:00PM
The Preclinical Modeling and Discovery of Combinations
Room: Cascade Ballroom

Speaker 2 of 6
William R. Sellers, Broad Institute of MIT and Harvard, USA
Targeting Genetic Redundancy in Cancer through Combinatorial CRISPR Screens

Wednesday, January 22 | 5:00PM - 7:00PM
The Preclinical Modeling and Discovery of Combinations
Room: Cascade Ballroom

Speaker 3 of 6
Jonathan S. Weissman, Whitehead Institute and MIT, USA
Single-Cell-Resolution Lineage Tracing of Tumors in a Mouse Xenograft Model Reveals Rapid and Multidirectional Metastasis

Wednesday, January 22 | 5:00PM - 7:00PM
The Preclinical Modeling and Discovery of Combinations
Room: Cascade Ballroom

Speaker 4 of 6
Peter Sorger, Harvard Medical School, USA
Adaptation of BRAF-Mutant Melanoma Cells to RAF/MEK Inhibitors and Subsequent Progression to Drug Resistance

Wednesday, January 22 | 5:00PM - 7:00PM
The Preclinical Modeling and Discovery of Combinations
Room: Cascade Ballroom

Speaker 5 of 6
Kasey L. Couts, University of Colorado Denver, USA
Short Talk: Loss of Innate Immune Sensing Contributes to Mucosal Melanoma Development and Immunotherapy Resistance

Wednesday, January 22 | 5:00PM - 7:00PM
The Preclinical Modeling and Discovery of Combinations
Room: Cascade Ballroom

Speaker 6 of 6
Sophia Wild, University of Cambridge, UK
Short Talk: ClonEx-Seq: Characterising Clonal Evolution in Time and Space with a Toolkit of Expressable Barcodes

Wednesday, January 22 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Alberta/New Brunswick
No registration fees are used to fund alcohol served at this function.

Wednesday, January 22 | 7:30PM - 10:00PM
Poster Session 3
Room: Alberta/New Brunswick


Thursday, January 23 | 7:00AM - 8:00AM
Breakfast
Room: Alberta/New Brunswick


Thursday, January 23 | 8:00AM - 11:00AM
Therapeutic Combinations
Room: Cascade Ballroom

Speaker 1 of 7
* Hunter Shain, University of California, San Francisco, USA

Thursday, January 23 | 8:00AM - 11:00AM
Therapeutic Combinations
Room: Cascade Ballroom

Speaker 2 of 7
Lillian L. Siu, Princess Margaret Hospital, Canada
Oncology Drug Combinations - Are We at an Impasse?

Thursday, January 23 | 8:00AM - 11:00AM
Therapeutic Combinations
Room: Cascade Ballroom

Speaker 3 of 7
Steven Stein, Incyte, USA
The Development of IO Combinations

Thursday, January 23 | 8:00AM - 11:00AM
Therapeutic Combinations
Room: Cascade Ballroom


Coffee Break

Thursday, January 23 | 8:00AM - 11:00AM
Therapeutic Combinations
Room: Cascade Ballroom

Speaker 5 of 7
Shumei Kato, University of California, San Diego Moores Cancer Center, USA
N-of-1 Biomarker-Based Customized Combination Therapy: The PREDICT Family of Studies

Thursday, January 23 | 8:00AM - 11:00AM
Therapeutic Combinations
Room: Cascade Ballroom

Speaker 6 of 7
Akash Mitra, University of Texas MD Anderson Cancer Center, USA
Short Talk: Immune Enrichment and T-Cell Receptor (TCR) Frequencies Predict Response to Immune Checkpoint Blockade (ICB) in Sarcoma

Thursday, January 23 | 8:00AM - 11:00AM
Therapeutic Combinations
Room: Cascade Ballroom

Speaker 7 of 7
Anna Vilgelm, Ohio State University, USA
Short Talk: Combination Treatment with MDM2 Antagonist Overcomes Intrinsic Resistance to CDK4/6 Inhibition

Thursday, January 23 | 11:00AM - 5:00PM
On Own for Lunch


Thursday, January 23 | 4:30PM - 5:00PM
Coffee Available
Room: Riverview Lounge


Thursday, January 23 | 5:00PM - 6:45PM
Clinical Trials and Clinical Trial Design
Room: Cascade Ballroom

Speaker 1 of 4
* Viola Chen, Merck, USA

Thursday, January 23 | 5:00PM - 6:45PM
Clinical Trials and Clinical Trial Design
Room: Cascade Ballroom

Speaker 2 of 4
Tatiana Prowell, U.S. FDA and Johns Hopkins University, USA
The Regulatory View on the Development of Combination Therapeutics

Thursday, January 23 | 5:00PM - 6:45PM
Clinical Trials and Clinical Trial Design
Room: Cascade Ballroom

Speaker 3 of 4
Jeanne Tie, Peter MacCallum Cancer Centre / Walter & Eliza Hall Institute, Australia
Can Circulating Tumor DNA Re-Define the Adjuvant Treatment Paradigm?

Thursday, January 23 | 5:00PM - 6:45PM
Clinical Trials and Clinical Trial Design
Room: Cascade Ballroom

Speaker 4 of 4
Antoni Ribas, University of California, Los Angeles, USA
Testing I/O Combinations in Clinical Trials

Thursday, January 23 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Cascade Ballroom


Thursday, January 23 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Alberta/New Brunswick
No registration fees are used to fund alcohol served at this function.

Thursday, January 23 | 8:00PM - 11:00PM
Entertainment
Room: Alberta/New Brunswick
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Friday, January 24 | 10:24AM - 10:24AM
Departure


*Session Chair.